Cargando…

Fatigue is independently associated with disease activity assessed using the Physician Global Assessment but not the SLEDAI in patients with systemic lupus erythematosus

OBJECTIVES: To analyse whether reported fatigue, one of the most challenging manifestations of systemic lupus erythematosus (SLE), may bias the assessment of disease activity in SLE according to the Physician Global Assessment (PGA). METHODS: Patients from the Lupus BioBank of the upper Rhein databa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mertz, Philippe, Piga, Matteo, Chessa, Elisabetta, Amoura, Zahir, Voll, Reinhard E, Schwarting, Andreas, Maurier, Francois, Blaison, Gilles, Bonnotte, Bernard, Poindron, Vincent, Fiehn, Christoph, Lorenz, Hanns-Martin, Korganow, Anne-Sophie, Sibilia, Jean, Martin, Thierry, Arnaud, Laurent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Lupus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486369/ https://www.ncbi.nlm.nih.gov/pubmed/36123013 http://dx.doi.org/10.1136/rmdopen-2022-002395

Ejemplares similares

Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations
por: Meyer, Aurore, et al.
Publicado: (2020)

Circulating mitochondrial DNA copy numbers represent a sensitive marker for diagnosis and monitoring of disease activity in systemic lupus erythematosus
por: Giaglis, Stavros, et al.
Publicado: (2021)

Systemic lupus erythematosus: state of the art on clinical practice guidelines
por: Tamirou, Farah, et al.
Publicado: (2019)

Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study
por: Floris, Alberto, et al.
Publicado: (2022)

Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis
por: Morand, Eric, et al.
Publicado: (2023)

Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2020)

Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies
por: Holmqvist, Marie, et al.
Publicado: (2015)

Differential regulation of the interferon response in systemic lupus erythematosus distinguishes patients of Asian ancestry
por: Rector, Ian, et al.
Publicado: (2023)

Development and external validation of a prediction model for venous thromboembolism in systemic lupus erythematosus
por: You, Hanxiao, et al.
Publicado: (2023)

Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis
por: Yazdany, Jinoos, et al.
Publicado: (2020)

White matter hyperintensities associate with cognitive slowing in patients with systemic lupus erythematosus and neuropsychiatric symptoms
por: Monahan, Rory Caitlin, et al.
Publicado: (2021)

Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice
por: Tanaka, Yoshiya
Publicado: (2023)

Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus
por: Tydén, Helena, et al.
Publicado: (2017)

Validation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in an academic tertiary care centre
por: Schmidtmann, Irene, et al.
Publicado: (2023)

Preclinical to clinical translation of cenerimod, a novel S1P(1) receptor modulator, in systemic lupus erythematosus
por: Strasser, Daniel S, et al.
Publicado: (2020)

Impact of fatigue on health-related quality of life and illness perception in a monocentric cohort of patients with systemic lupus erythematosus
por: Elefante, Elena, et al.
Publicado: (2020)

Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial
por: Wang, Huijing, et al.
Publicado: (2022)

Performance of the proposed ACR–EULAR classification criteria for systemic lupus erythematosus (SLE) in a cohort of patients with SLE with neuropsychiatric symptoms
por: Gegenava, Maka, et al.
Publicado: (2019)

Absence of Anti-Glomerular Basement Membrane Antibodies in 200 Patients With Systemic Lupus Erythematosus With or Without Lupus Nephritis: Results of the GOODLUPUS Study
por: Bourse Chalvon, Nellie, et al.
Publicado: (2020)

The impact of upper limb exercise on function, daily activities and quality of life in systemic lupus erythematosus: a pilot randomised controlled trial
por: Keramiotou, Kyriaki, et al.
Publicado: (2020)

Increased risk of congenital malformations in offspring born to women with systemic lupus erythematosus in South Korea: a nationwide population-based study
por: Jung, Young Mi, et al.
Publicado: (2023)

Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience
por: Tani, Chiara, et al.
Publicado: (2019)

Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years
por: Zhang, Fengchun, et al.
Publicado: (2022)

Validation of a machine learning approach to estimate Systemic Lupus Erythematosus Disease Activity Index score categories and application in a real-world dataset
por: Alves, Pedro, et al.
Publicado: (2021)

Lipid management in systemic lupus erythematosus according to risk classifiers suggested by the European Society of Cardiology and disease-related risk factors reported by the EULAR recommendations
por: Drosos, George C, et al.
Publicado: (2023)

Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Genetic dissection of HLA-DRB1*15:01 and XL9 region variants in Japanese patients with systemic lupus erythematosus: primary role for HLA-DRB1*15:01
por: Kawasaki, Aya, et al.
Publicado: (2023)

Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020–2021
por: Calabrese, Cassandra, et al.
Publicado: (2023)

Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2019)

Brief Report: A Randomized, Double‐Blind, Parallel‐Group, Placebo‐Controlled, Multiple‐Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis
por: Cheng, Laurence E., et al.
Publicado: (2018)

Multicentre retrospective cohort study assessing the incidence of serious infections in patients with lupus nephritis, compared with non-renal systemic lupus erythematosus
por: Yates, Drew Joseph, et al.
Publicado: (2020)

Reduction in SLEDAI is associated with improved arterial stiffness in systemic lupus erythematosus
por: Du, Tian, et al.
Publicado: (2020)

Blockade of Interferon‐γ Normalizes Interferon‐Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus
por: Welcher, Andrew A., et al.
Publicado: (2015)

Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients
por: Isenberg, D., et al.
Publicado: (2017)

Clinical measurement of lupus nephritis activity is inferior to biomarker-based activity assessment using the renal activity index for lupus nephritis in childhood-onset systemic lupus erythematosus
por: Aljaberi, Najla, et al.
Publicado: (2022)

Validation of the Cutaneous Lupus Erythematosus Disease Area and Severity Index and pSkindex27 for use in childhood-onset systemic lupus erythematosus
por: AlE'ed, Ashwaq, et al.
Publicado: (2018)

Robust measurement of clinical improvement in patients with cutaneous lupus erythematosus
por: Nanes, Benjamin A, et al.
Publicado: (2020)

Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis
por: Boedigheimer, Michael J, et al.
Publicado: (2017)

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus
por: Doria, A., et al.
Publicado: (2018)

Plucked hair follicles from patients with chronic discoid lupus erythematosus show a disease-specific molecular signature
por: Shalbaf, Mohammad, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_oiqfbujhfb9g44dkso93l035df